title: Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia?
abstract: The presence of hypoxia is a general feature of most solid malignancies, and hypoxia is considered as one of major factors for anticancer therapy failure. Carbonic anhydrase IX (CAIX) has been reported to be an endogenous hypoxia marker, CAIX monoclonal antibodies, their segments and inhibitors are developed for CAIX imaging. However, growing evidence indicates that CAIX expression under hypoxia condition may be cancer cell lines or cancer-type dependent. Here we review the current literature on CAIX and discuss the advantage and limitation of CAIX as a target for tumor hypoxia imaging. Accordingly, CAIX would be unreliable as a universal target for cancer and tumor hypoxia visualization.
authors.affiliation: Department of Nuclear Medicine, Inner Mongolia Medical University Affiliated Hospital, Hohhot, Inner Mongolia, China.
authors.forename: Jianbo
authors.initials: J
authors.lastname: Li
authors.forename: Guojian
authors.initials: G
authors.lastname: Zhang
authors.forename: Xuemei
authors.initials: X
authors.lastname: Wang
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: Li
mesh_terms: D000818:Animals; D002256:Carbonic Anhydrases / Q000378:metabolism*; D004195:Disease Models, Animal; D006801:Humans; D000860:Hypoxia / Q000378:metabolism*; D007527:Isoenzymes; D057054:Molecular Imaging / Q000379:methods; D009369:Neoplasms / Q000175:diagnosis* / Q000378:metabolism*
chemical_list: D007527:Isoenzymes; D002256:Carbonic Anhydrases
keywords: cancer; carbonic anhydrase IX; hypoxia; molecular imaging